Flag of the European Union EU Clinical Trials Register Help

Clinical trials for glioblastoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    235 result(s) found for: glioblastoma. Displaying page 3 of 12.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-002417-21 Sponsor Protocol Number: AK2016-2 Start Date*: 2016-09-22
    Sponsor Name:Rigshospitalet
    Full Title: uPAR-PET/MR in glioma
    Medical condition: Gliomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003138-17 Sponsor Protocol Number: MO28347 Start Date*: 2013-06-13
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A double-blind, placebo-controlled, randomised, Phase II study evaluating the efficacy and safety of addition of continuous multiple line bevacizumab treatment to lomustine in second (2nd)-line f...
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) LT (Prematurely Ended) IT (Completed) IE (Prematurely Ended) EE (Prematurely Ended) GB (Prematurely Ended) LV (Prematurely Ended) ES (Completed) FI (Prematurely Ended) SE (Completed) PT (Prematurely Ended) BG (Prematurely Ended) GR (Completed) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002539-27 Sponsor Protocol Number: PI2011_843_0001 Start Date*: 2013-03-05
    Sponsor Name:CHU Amiens
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002606-54 Sponsor Protocol Number: 8/2006 Start Date*: 2006-03-02
    Sponsor Name:ASL SALERNO 1
    Full Title: Investigational use of 5-ALA for fluorescence-guided resection of malignant glioma
    Medical condition: Glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    6.1 10018336 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002142-37 Sponsor Protocol Number: SURGE 01-07 Start Date*: 2007-08-03
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: SUNITINIB (SUTENT, SU11248) in Patients with Recurrent or Progressive Glioblastoma multiforme An Academic Prospective Single-arm Phase II Clinical Trial including Translational Research Studies
    Medical condition: Glioblastoma multiforme - WHO grade IV First progression/recurrence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001977-13 Sponsor Protocol Number: 020221 Start Date*: 2012-08-01
    Sponsor Name:Northwest Biotherapeutics Inc
    Full Title: A Phase III clinical trial evaluating DCVax®-L, autologous dendritic cells (DC) pulsed with tumor lysate antigen for the treatment of glioblastoma multiforme (GBM)
    Medical condition: Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002801-36 Sponsor Protocol Number: Can-201 Start Date*: 2023-03-08
    Sponsor Name:Cantex Pharmaceuticals Inc.
    Full Title: A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon Combined with Conventional Concurrent Radiation and Temozolomide in Patients with Newly...
    Medical condition: Newly diagnosed glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004418-40 Sponsor Protocol Number: H9H-MC-JBAL Start Date*: 2012-02-23
    Sponsor Name:Lilly S.A,
    Full Title: A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate plus Lomustine Therapy compared to Lomustine Monotherapy in Patients with Recurrent Glioblastoma
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) IT (Completed) PL (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021531-13 Sponsor Protocol Number: UCL/10/0035 Start Date*: 2011-02-17
    Sponsor Name:Joint UCLH and UCL Biomedical Research Unit
    Full Title: Multi-centre, randomised, double-blind phase II study comparing cediranib (AZD2171) plus gefitinib (Iressa, ZD1839) with cediranib plus placebo in subjects with recurrent/progressive glioblastoma (...
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004552-15 Sponsor Protocol Number: NANO-GBM Start Date*: 2021-03-18
    Sponsor Name:Centre Jean Perrin
    Full Title: Phase I/II study of AGuIX nanoparticles with radiotherapy plus concomitant Temozolomide in the treatment of newly diagnosed glioblastoma
    Medical condition: glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002727-25 Sponsor Protocol Number: UKM12_0017 Start Date*: 2017-10-20
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Controlled clinical trial to evaluate the safety and efficacy of stereotactical photodynamic therapy with 5-aminolevulinic acid (Gliolan®) in recurrent glioblastoma
    Medical condition: Recurrent glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023218-30 Sponsor Protocol Number: 26101 Start Date*: 2012-12-13
    Sponsor Name:EORTC
    Full Title: Phase III trial exploring the combination of bevacizumab and loumustine in patients with first recurrence of a glioblastoma.
    Medical condition: Recurrent glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003738-34 Sponsor Protocol Number: CA209-143 Start Date*: 2014-06-05
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (GBM)...
    Medical condition: Recurrent glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed) BE (Completed) DK (Completed) PL (Completed) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002685-23 Sponsor Protocol Number: ICT-107-301 Start Date*: 2016-08-19
    Sponsor Name:ImmunoCellular Therapeutics, Ltd.
    Full Title: A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy.
    Medical condition: Treatment of newly diagnosed glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) NL (Ongoing) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004064-62 Sponsor Protocol Number: SNOXA12C401 Start Date*: 2019-05-07
    Sponsor Name:TME Pharma AG
    Full Title: Single-arm, dose-escalation Phase 1/2 Study of olaptesed pegol (NOX-A12) in combination with irradiation in inoperable or partially resected first-line glioblastoma patients with unmethylated MGMT ...
    Medical condition: glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000900-16 Sponsor Protocol Number: UZB-BN-11-001 Start Date*: 2011-05-05
    Sponsor Name:UZ BRUSSEL
    Full Title: AA randomized phase II clinical trial on the efficacy of axitinib as a monotherapy or in combination with lomustine for the treatment of patients with recurrent glioblastoma
    Medical condition: • Patients with recurrent central nervous system glioblastoma (histologically confirmed WHO grade IV glioma), at documented recurrence/progression following prior treatment with surgery, radiation ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004058-17 Sponsor Protocol Number: CV-006 Start Date*: 2016-02-22
    Sponsor Name:CytoVac A/S
    Full Title: An open-label, randomised, Phase II study to investigate the efficacy and safety of ALECSAT treatment as an add-on therapy to radiotherapy and temozolomide in patients with newly diagnosed gliobl...
    Medical condition: Glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004631-92 Sponsor Protocol Number: WWU20_0041 Start Date*: 2022-07-26
    Sponsor Name:Westfälische Wilhelms-Universität Münster, C/o Universitätsklinikum Münster Geschäftsbereich Recht u. Drittmittel
    Full Title: Phase I/II dose escalation trial of radiodynamic therapy (RDT) with 5-Aminolevulinic acid in patients with first recurrence of glioblastoma
    Medical condition: recurrence of glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003722-41 Sponsor Protocol Number: IOV–GB–1-2014-REGOMA Start Date*: 2015-04-24
    Sponsor Name:Istituto Oncologico Veneto – IOV‐IRCCS
    Full Title: Regorafenib in relapsed glioblastoma. REGOMA study Randomized, controlled open‐label phase II clinical trial
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000708-39 Sponsor Protocol Number: NEU-201901 Start Date*: 2021-07-16
    Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn
    Full Title: Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy
    Medical condition: Adult patients with IDHwt, MGMT promotor methylated glioblastoma at first relapse
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 28 03:33:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA